FZD4 and cancer: In conclusion, the expanding arsenal of GPCR‐targeted therapeutics, including small‐molecule agonists and antagonists, biased ligands, mAbs, nanobodies, aptamers, gene therapies, and novel approaches like PROTACs, reflects the central and multifaceted role of GPCRs in cancer biology and treatment.